By Sofia Melliou
The buzz around artificial intelligence (AI) in drug discovery is undeniable, but a major bottleneck remains. There are no openly available, high-quality, large-scale datasets needed to train machine…
The Structural Genomics Consortium (SGC) is pleased to announce that Dr. Rachel Harding, Principal Investigator at SGC-Toronto, has been awarded a Canadian Institutes of Health Research (CIHR) Fall 2024 Project Grant for her research project, "Macrocyclic Peptides to Uncover Huntington Disease…
As the Structural Genomics Consortium (SGC) enters its third decade, it is embarking on an ambitious goal: to become the world’s largest generator of open-source protein-ligand data. Recognizing the growing importance of data science in early-stage drug discovery, SGC…
The human immune system serves as our body’s defense against harmful pathogens and cancer by identifying and eliminating abnormal cells. To maintain immune homeostasis several mechanisms are employed, which involve a wide range of proteins, including the Casitas B…
Cheryl Arrowsmith, Chief Scientist of the Structural Genomics Consortium (SGC), Senior Scientist at the Princess Margaret Cancer Centre, and Professor at the Department of Medical Biophysics at the University of Toronto, has been recognized by UBC Medicine for her…
We are thrilled to share the news that Dr. Rachel Harding, Principal Investigator at the SGC-Toronto, has taken on the role of Assistant Professor in the Department of Pharmaceutical Sciences at the Leslie Dan Faculty of Pharmacy, University of Toronto.
…
The Structural Genomics Consortium at the University of Toronto is thrilled to announce that Assistant Professor and Principal Investigator, Dr. Rachel Harding, has been honored with the Hereditary Disease Foundation’s (HDF) 2024 Nancy S. Wexler Young Investigator…
On Monday February 9th, 2015, SGC Toronto hosted the one-day workshop EZH2 inhibitors: Target Validation through Chemical Biology focusing on discussion and sharing of data around the use of inhibitors of EZH2.
“EZH2 is a major regulator of epigenetic states and an important clinical…